Compare BioNano Genomics Inc (BNGO) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs IAC/Interactivecorp — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while IAC/Interactivecorp trades at $46 (market cap $3.37B). The key difference: IAC/Interactivecorp is far larger — about 255.3× BioNano Genomics Inc's market cap, and IAC/Interactivecorp is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | PPLI | |
|---|---|---|
Market Cap | $13.20M | $3.37B |
Sector | Health | Media |
52-Week High | $4.92 | $47.62 |
52-Week Low | $1.09 | $31.52 |
Enterprise Value | $15.81M | $3.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
PPLI trades at $45.89, down 1.31% today, with a mixed technical outlook showing bullish moving averages but neutral oscillators. The company reported a net loss of $104.03M in 2025, missing earnings expectations for three consecutive quarters. Recent news indicates potential acquisition interest from MGM Resorts, adding speculative momentum. The stock's valuation metrics show a low P/B of 0.75 but a high P/E of 28.17, reflecting investor uncertainty about profitability.
The outlook is cautiously optimistic due to strong analyst support (63.64% buy ratings) and a $55.40 consensus price target, suggesting 21% upside. However, persistent earnings misses, negative cash flow trends, and high debt levels pose significant risks. Revenue decline from $5.2B in 2022 to $2.4B in 2025 highlights operational challenges that need addressing for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
